Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Haematological Improvement in Patients With Low-risk MDS by Comparing VBaP With Danazol in Patients Who Have Either Received Erythropoiesis Stimulating Agents (ESA) and Lost Response, Not Responded to ESA or Are Deemed Unlikely to Respond to ESA

NCT04997811 is registered in ClinicalTrials.gov with Prof. Janet Dunn as lead sponsor.

NCT NCT04997811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04997811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Haematological Improvement in Patients With Low-risk MDS by Comparing VBaP With Danazol in Patients Who Have Either Received Erythropoiesis Stimulating Agents (ESA) and Lost Response, Not Responded to ESA or Are Deemed Unlikely to Respond to ESA
Lead sponsor
Prof. Janet Dunn
Phase
Phase 2
Overall status
Unknown status
Start date
December 21, 2021
Completion date
June 30, 2025
Enrollment
120 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes (mds)